Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years

Condition:   Meningitis, Meningococcal Interventions:   Biological: MenABCWY vaccine;   Biological: rMenB+OMV NZ (Bexsero) vaccine;   Biological: MenACWY (Menveo) vaccine Sponsor:   GlaxoSmithKline Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials